

Surrozen submitted an IND application to the FDA for SZN-8141 to treat diabetic macular edema, with trial data expected in late 2027.
You can purchase shares of Surrozen (NASDAQ:SRZN) through any online brokerage.
Other companies in Surrozen’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Surrozen has a consensus price target of $65.33.
The stock price for Surrozen (NASDAQ: SRZN) is $31.63 last updated November 12, 2026 at 9:34 AM EST.
There are no upcoming dividends for Surrozen.
Surrozen does not have any upcoming earnings scheduled.
There is no upcoming split for Surrozen.
Surrozen is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product...